Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 71

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 71
---
,352,012 | ) |
| Deemed dividend                              |     | $                           |          - |   |     | $             | - |     | $        | (44,039,045 | ) |     | $       | (44,039,045 | ) |
| Net loss attributable to common shareholders |     | $                           |          - |   |     | $             | - |     | $        | (44,039,045 | ) |     | $       | (52,391,056 | ) |

| 41 |

On November 20, 2025, we entered into a binding
letter of intent (the “LOI”) with Telomir Pharmaceuticals, Inc. Inc. (“TELI”), a privately held Delaware corporation,
which is a related party due to certain common shareholders and licensor, to acquire TELI through a stock-for-stock merger with Telipharm
Acquisition, Inc., our merger subsidiary. TELI will be the survivor of this merger and will become our wholly owned subsidiary.

The transaction will be recorded as an asset acquisition
from a related party at acquired cost basis with two assets to be acquired, the license agreement and $1,000,000 in cash or marketable
securities. TELI is a newly formed legal entity with no revenue, no employees, no facilities, and no infrastructure. TELI has no operating
history, with no revenues and expenses. TELI’s assets as of the Merger Date will consist exclusively of the $1,000,000 in cash
or marketable securities and the Telo-1 license agreement with MIRALOGX. MIRALOGX is the licensor of TELO’s and TELI’s rights
to Telomir-1. MIRALOGX is a separate intellectual property development company owned by the Bayshore Trust. The Bayshore Trust is also
TELI’s largest stockholder. The license agreement grants rights to develop and commercialize the Telomir-1 compound in the
United Arab Amirates, Australia, Canada, China, European Union, Israel, India, Japan, South Korea, Mexico, Argentina, Taiwan and Uruguay.
No other tangible or intangible assets, such as equipment, customer relationships, or developed technologies, will be transferred. The
TELI entity lacks any organized workforce, contractual arrangements with third parties, or operational infrastructure necessary to apply
processes to inputs in a way that could generate outputs. There